Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Rating) – Equities researchers at SVB Leerink raised their Q1 2023 earnings per share estimates for Atea Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst R. Ruiz now anticipates that the company will post earnings of ($0.50) per share for the quarter, up from their […]
Related Keywords
, Morgan Stanley , Geode Capital Management , Atea Pharmaceuticals Trading , Blackrock Inc , Nasdaq , Vanguard Group Inc , News Ratings For Atea Pharmaceuticals Daily , Atea Pharmaceuticals , Atea Pharmaceuticals Inc , Hermes Inc , Institutional Trading Of Atea Pharmaceuticals , Get Rating , Atea Pharmaceutical , Street Corp , Capital Management , Atea Pharmaceuticals Daily , Nasdaq Avir , Tavir , Medical , Earnings Estimates , Svb Leerink Llc ,
comparemela.com © 2020. All Rights Reserved.